Randomised double blind placebo controlled trial of inhaled fluticasone propionate in infants with chronic lung...

Area of Science:

• Pediatrics
• Pulmonology
• Clinical Trials

Background:

• Chronic lung disease (CLD) is a significant concern in infants.
• Effective treatments for CLD symptoms in infants are crucial.
• Fluticasone propionate is an inhaled corticosteroid with potential anti-inflammatory effects.

Purpose of the Study:

• To evaluate the efficacy of fluticasone propionate in managing chronic lung disease symptoms in infants.
• To compare the effects of fluticasone propionate versus placebo on infant respiratory outcomes.

Main Methods:

• A double-blind, randomized controlled trial was conducted.
• Thirty infants diagnosed with chronic lung disease were enrolled.
• Participants received either fluticasone propionate or a placebo for one year.

Main Results:

• No statistically significant differences were observed between the fluticasone propionate and placebo groups.
• Incidence of day and night time symptoms did not differ between groups.
• Other measured outcome parameters showed no significant variations.

Conclusions:

• Fluticasone propionate did not demonstrate a significant benefit over placebo for infants with chronic lung disease.
• Further research may be needed to explore alternative or adjunctive therapies for CLD in this population.